Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 9, 2005
Last updated: September 21, 2006
Last verified: September 2006
To determine if the NMDA antagonist, CP-101,606, is effective for depression

Condition Intervention Phase
Depressive Disorder, Major
Drug: NMDA Antagonist, CP-101,606 (traxoprodil)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:

Secondary Outcome Measures:
  • HAM-D

Estimated Enrollment: 30
Study Start Date: May 2004
Estimated Study Completion Date: December 2005

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary DSM-IV diagnosis of MDD

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00163059

United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States, 67214-2878
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information: Identifier: NCT00163059     History of Changes
Other Study ID Numbers: A1611006 
Study First Received: September 9, 2005
Last Updated: September 21, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antidepressive Agents
Psychotropic Drugs processed this record on October 28, 2016